目的 觀察黃葵膠囊聯(lián)合他克莫司和潑尼松治療特發(fā)性膜性腎病的臨床療效。方法 選擇新鄉(xiāng)醫(yī)學(xué)院第一附屬醫(yī)院2015年3月—2016年12月就診的特發(fā)性膜性腎病患者86例，隨機(jī)分為對(duì)照組和治療組，每組各43例。對(duì)照組患者餐前1 h口服他克莫司膠囊，0.05 mg/（kg·d），2次/d；同時(shí)口服醋酸潑尼松片，30 mg/d。治療后患者在對(duì)照組的基礎(chǔ)上口服黃葵膠囊，5粒/次，3次/d。兩組患者均連續(xù)治療12周。治療后，觀察兩組患者臨床療效，同時(shí)比較治療前后兩組患者觀察指標(biāo)和不良反應(yīng)情況。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為81.39%、95.35%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P< 0.05）。治療后，兩組患者24 h尿蛋白定量和總膽固醇水平顯著降低，血清白蛋白明顯升高，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P< 0.05）；且治療組患者上述指標(biāo)顯著優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P< 0.05）。兩組不良反應(yīng)發(fā)生情況比較差異無(wú)統(tǒng)計(jì)學(xué)意義。結(jié)論 黃葵膠囊聯(lián)合他克莫司和潑尼松治療特發(fā)性膜性腎病療效明顯，安全性較好，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To observe the clinical effect of Huangkui Capsules combined with tacrolimus and prednisone in treatment of idiopathic membranous nephropathy. Methods Patients (86 cases) with idiopathic membranous nephropathy in the First Affiliated Hospital of Xinxiang Medical University from March 2015 to December 2016 were randomly divided into control group and treatment group, and each group had 43 cases. Patients in the control group were po administered with Tacrolimus Capsules 1 h before meals, 0.1 mg/(kg·d), twice daily; And they were po administered with Prednisone Acetate Tablets, 30 mg/d. Patients in the treatment group were po administered with Huangkui Capsules on the basis of the control group, five grains/time, three times daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacy was evaluated, and observational indexes and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 81.39% and 95.35% respectively, and there was difference between two groups (P < 0.05). After treatment, the levels of 24 h urine protein and total cholesterol were significantly decreased, but serum albumin was significantly increased, the difference was statistically significant in the same group (P < 0.05). And those indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). There was no significant difference in adverse reactions between two groups.Conclusion Huangkui Capsules combined with tacrolimus and prednisone has a significant curative effect in treatment of idiopathic membranous nephropathy with good safety, which has a certain clinical application value.